The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10241 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether-lumefantrine (AL)

Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania

March 26, 2019 - 15:45 -- Open Access
Tags: 
Author(s): 
Deus S. Ishengoma, Celine I. Mandara, Venkatachalam Udhayakumar, et al.
Reference: 
Malaria Journal 2019 18:88, 21 March 2019

The study indicated high efficacy of AL and the safety profile was consistent with previous reports.

Country: 
Medical Treatment: 

Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis

June 21, 2018 - 17:12 -- Open Access
Author(s): 
Frank Kloprogge, Lesley Workman, Joel Tarning, et al.
Reference: 
PLoS Med 15(6): e1002579

Our findings suggest that revised AL dosing regimens for young children and pregnant women would improve drug exposure but would require longer or more complex schedules.

Medical Treatment: 

Sustained Ex Vivo Susceptibility of Plasmodium falciparum to Artemisinin Derivatives but Increasing Tolerance to Artemisinin Combination Therapy Partner Quinolines in The Gambia

November 25, 2017 - 14:55 -- Open Access
Author(s): 
Alfred Amambua-Ngwa, Joseph Okebe, Umberto D'Alessandro, et al.
Reference: 
Antimicrob. Agents Chemother. December 2017 vol. 61 no. 12 e00759-17

Antimalarial interventions have yielded a significant decline in malaria prevalence in The Gambia, where artemether-lumefantrine (AL) has been used as a first-line antimalarial for a decade.

Country: 
Medical Treatment: 

NOT Open Access | K13 Propeller Alleles, mdr1 Polymorphism, and Drug Effectiveness at Day 3 after Artemether-Lumefantrine Treatment for Plasmodium falciparum Malaria in Colombia, 2014-2015

November 25, 2017 - 14:52 -- NOT Open Access
Author(s): 
Madeline Montenegro, Aaron T. Neal, Maritza Posada, Briegel De las Salas, Tatiana M. Lopera-Mesa, Rick M. Fairhurst and Alberto Tobon-Castaño
Reference: 
Antimicrob. Agents Chemother. December 2017 vol. 61 no. 12 e01036-17

High treatment failure rates for Plasmodium falciparum malaria have been reported in Colombia for chloroquine, amodiaquine, and sulfadoxine-pyrimethamine.

Country: 
Medical Treatment: 

Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau – An Open-Label Non-Inferiority Randomised Clinical Trial

October 5, 2016 - 17:38 -- Open Access
Author(s): 
Johan Ursing, Lars Rombo, Amabelia Rodrigues, Poul-Erik Kofoed
Reference: 
PLoS ONE 11(9): e0161495

Both treatments achieved the WHO recommended efficacy for antimalarials about to be adopted as policy.

Background

Artemether-lumefantrine (AL) was introduced for treatment of uncomplicated malaria in Guinea-Bissau in 2008. Malaria then resurged and recurrent malaria after treatment with AL and stock-outs of AL were common. This study therefore aimed to assess the efficacy of AL and identify an alternative second line antimalarial. Dihydroartemisinin-piperaquine (DP) was chosen as it has been shown to be safe and efficacious and to reduce the incidence of recurrent malaria.

Medical Treatment: 

Malaria in urban, semi-urban and rural areas of southern of Gabon: comparison of the Pfmdr 1 and Pfcrt genotypes from symptomatic children

August 23, 2016 - 16:39 -- Open Access
Author(s): 
Sydney Maghendji-Nzondo, Lady-Charlène Kouna, Jean Bernard Lekana-Douki, et al.
Reference: 
Malaria Journal 2016 15:420, 18 August 2016

This study shows an increase in the prevalence of childhood plasmodial infection in Gabon according to the low socio-economic level, and a high frequency of markers associated with AL treatment failure.

Medical Treatment: 

In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014

April 26, 2016 - 18:27 -- Open Access
Tags: 
Author(s): 
Magdalena Paczkowski, Dyson Mwandama, Daniel Marthey, Madalitso Luka, Georgina Makuta, John Sande, Doreen Ali, Peter Troell, Don P. Mathanga and Julie Gutman
Reference: 
Malaria Journal 2016 15:236, 26 April 2016

As evidenced by the day 28 PCR-corrected cumulative success rates, both AL and ASAQ remain efficacious treatments for uncomplicated malaria in Malawi.

Medical Condition: 
Medical Treatment: 

High efficacy of two artemisinin-based combinations: artesunate + sulfadoxine-pyrimethamine and artemether-lumefantrine for falciparum malaria in Yemen

November 18, 2015 - 14:08 -- Open Access
Author(s): 
Ahmed Adeel, Niaz Saeed, Rania Nada, et al.
Reference: 
Malaria Journal 2015, 14:449 (14 November 2015)

AS + SP remains the effective drug for uncomplicated falciparum malaria in Yemen.

Medical Treatment: 

Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study

November 4, 2015 - 11:55 -- Open Access
Author(s): 
Mathieu Ndounga, Pembe Issamou Mayengue, Francine Ntoumi, et al.
Reference: 
Malaria Journal 2015, 14:423 (29 October 2015)

This first randomized study in Brazzaville confirmed the excellent efficacy of these co-formulated anti-malarial drugs in children.

Person: 
Medical Treatment: 

Strategies for Understanding and Reducing the Plasmodium vivax and Plasmodium ovale Hypnozoite Reservoir in Papua New Guinean Children: A Randomised Placebo-Controlled Trial and Mathematical Model

October 29, 2015 - 05:58 -- Open Access
Author(s): 
Leanne J. Robinson, Rahel Wampfler, Ivo Mueller, et al.
Reference: 
PLoS Med 12(10): e1001891

These results suggest that relapses cause approximately four of every five P. vivax infections and at least three of every five P. ovale infections in PNG children and are important in sustaining transmission.

Medical Treatment: 

Pages

Subscribe to RSS - artemether-lumefantrine (AL)